Infant Bacterial Therapeutics AB (publ) (IBT-B) — Cash Flow Quality Index

Latest as of June 2022: -17.11x

Infant Bacterial Therapeutics AB (publ) (IBT-B) has a Cash Flow Quality Index of -17.11x as of June 2022. Operating cash flow of Skr-30.09 Million is below net income of Skr1.76 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Infant Bacterial Therapeutics AB (publ) (IBT-B) cash conversion ratio to assess how effectively this company generates cash.

Cash Flow Quality Index

-17.11x

Operating CF / Net Income

Operating Cash Flow

Skr-30.09 Million

SEK

Net Income

Skr1.76 Million

SEK

Data as of

Jun 2022

Most recent filing

Annual Cash Flow Quality Index for Infant Bacterial Therapeutics AB (publ) (None–None)

Year-by-year earnings quality comparison for Infant Bacterial Therapeutics AB (publ). For live market cap and the full company financial profile, see market cap of Infant Bacterial Therapeutics AB (publ).

Year	Quality Index	Operating CF (SEK)	Net Income	YoY Change

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.